Form 4: Equillium Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Charles Douglas McDermott was granted 70,000 stock options in Equillium, Inc. as part of a standard equity incentive.
Summary
- Director Charles Douglas McDermott received a grant of 70,000 stock options for Equillium, Inc. (EQ) common stock.
- The options have an exercise price of $2.84 per share.
- The grant date for these options is May 28, 2026.
- The options are scheduled to expire on May 27, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility could impact the value of the options relative to the exercise price.
- The company's ability to maintain its share price above the $2.84 exercise price is subject to clinical and operational performance.
Future Outlook
The options vest in twelve equal monthly installments starting May 28, 2026, with full vesting guaranteed by the date of the next annual stockholders meeting.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though they are closely monitored by investors for potential dilution.
Comparison to Industry Standards
- The grant of 70,000 options is consistent with typical director compensation packages for small-cap biotechnology firms.
- Vesting schedules tied to annual meetings are a common governance practice to ensure director commitment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 70,000 stock options to Director Charles Douglas McDermott. | 05/28/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options in monthly installments.
- Potential exercise of options by the director upon vesting and subject to market conditions.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Grant date of the stock options and date of the earliest transaction. |
| 05/29/2026 | Date the Form 4 was signed and filed. |
| 05/27/2036 | Expiration date of the granted stock options. |
Keywords
Equillium, EQ, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.